<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-43836" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Soft Tissue Clear Cell Sarcoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zamora</surname>
            <given-names>Edgar A.</given-names>
          </name>
          <aff>Montefiore Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Greenwood</surname>
            <given-names>Anna C.</given-names>
          </name>
          <aff>VCU Medical Center/VCU</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cassaro</surname>
            <given-names>Sebastiano</given-names>
          </name>
          <aff>UN California Irvine / Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Edgar Zamora declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anna Greenwood declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sebastiano Cassaro declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-43836.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Clear cell sarcoma of soft tissue (CCSST) is an&#x000a0;ultra-rare&#x000a0;sarcoma originating from neural crest cells, most often presenting in young adults in the distal extremities. CCSST is histologically characterized by nests of clear cells separated by fibrous septa. These tumors share histological and immunohistochemical characteristics with malignant melanoma but are differentiated by a balanced gene translocation.&#x000a0;Due to its benign appearance, CCSST is sometimes initially misdiagnosed. However, this disease has a highly aggressive course, with a 5-year survival rate of around 50%.</p>
        <p>Diagnosis involves a combination of imaging, physical examination, and histological analysis, with confirmation through genetic testing for specific translocations. Treatment typically requires wide surgical resection with negative margins, though local recurrence and metastasis are common. Radiation and chemotherapy have shown limited effectiveness, and recent studies are exploring targeted therapies and immunotherapies.&#x000a0;This activity for healthcare professionals is designed to enhance the learner's competence in recognizing the clinical features of CCSST, performing the recommended evaluation, and implementing an appropriate interprofessional management approach, including&#x000a0;recent advances in systemic therapy to improve patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical presentation of clear cell sarcoma of soft tissue, including its common occurrence in young adults and distal extremities.</p></list-item><list-item><p>Differentiate&#x000a0;clear cell sarcoma of soft tissue from malignant melanoma and other soft tissue tumors using histological, immunohistochemical, and genetic features.</p></list-item><list-item><p>Screen for&#x000a0;clear cell sarcoma of soft tissue in patients presenting with suspicious soft tissue masses, particularly in the extremities of young adults.</p></list-item><list-item><p>Apply interprofessional team strategies to improve care coordination and outcomes&#x000a0;for patients affected by clear cell sarcoma of soft tissue.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=43836&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=43836">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-43836.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Clear cell sarcoma of soft tissue (CCSST) is an ultra-rare sarcoma originating from neural crest cells, first described by Enzinger in 1965.<xref ref-type="bibr" rid="article-43836.r1">[1]</xref><xref ref-type="bibr" rid="article-43836.r2">[2]</xref><xref ref-type="bibr" rid="article-43836.r3">[3]</xref>&#x000a0;The neoplasm primarily affects young adults, often presenting as slowly enlarging masses in the extremities, particularly around tendons or aponeuroses. The average patient is 34, though cases range in those aged from 2 to 90 years. Due to its benign appearance, CCSST is sometimes misdiagnosed early on, but it is highly aggressive, with a 5-year survival rate of around 50%.</p>
        <p>Diagnosis involves a combination of imaging, physical examination, and histological analysis, with confirmation through genetic testing for specific translocations. Treatment typically requires wide surgical resection with negative margins, though local recurrence and metastasis are common. Radiation and chemotherapy have shown limited effectiveness, and recent studies are exploring targeted therapies and immunotherapies.</p>
        <p>CCSST frequently metastasizes to the lungs, lymph nodes, and bone, with other sites like the brain and abdominal organs also reported. Despite ongoing research, the prognosis remains poor, particularly for larger tumors and metastatic disease, with survival heavily dependent on early detection and tumor stage.</p>
      </sec>
      <sec id="article-43836.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The&#x000a0;cause of clear cell sarcoma of soft tissues is unknown. CCSST is characterized by the gene translocation t(12;22)(q13;q12) resulting in<italic toggle="yes"> EWSR1:ATF1</italic> fusion gene or t(2;22)(q34;q12) resulting in <italic toggle="yes">EWSR1:CREB1</italic> fusion gene.<xref ref-type="bibr" rid="article-43836.r4">[4]</xref><xref ref-type="bibr" rid="article-43836.r5">[5]</xref><xref ref-type="bibr" rid="article-43836.r6">[6]</xref></p>
      </sec>
      <sec id="article-43836.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Clear cell sarcoma is classified as an ultra-rare sarcoma, with an incidence of 1 or less per 1,000,000 individuals.<xref ref-type="bibr" rid="article-43836.r1">[1]</xref>&#x000a0;The incidence is highest in White individuals, and CCSST is estimated to affect men and women equally.<xref ref-type="bibr" rid="article-43836.r7">[7]</xref><xref ref-type="bibr" rid="article-43836.r8">[8]</xref><xref ref-type="bibr" rid="article-43836.r9">[9]</xref><xref ref-type="bibr" rid="article-43836.r10">[10]</xref>&#x000a0;The average age of patients presenting with CCSST is 34; case series report an age range of 2 to 90 years.<xref ref-type="bibr" rid="article-43836.r11">[11]</xref><xref ref-type="bibr" rid="article-43836.r12">[12]</xref><xref ref-type="bibr" rid="article-43836.r13">[13]</xref><xref ref-type="bibr" rid="article-43836.r14">[14]</xref><xref ref-type="bibr" rid="article-43836.r15">[15]</xref><xref ref-type="bibr" rid="article-43836.r16">[16]</xref><xref ref-type="bibr" rid="article-43836.r17">[17]</xref><xref ref-type="bibr" rid="article-43836.r18">[18]</xref>&#x000a0;CCCST typically arises in the upper or lower extremities, particularly around the foot and ankle, and is associated with tendons and aponeuroses.<xref ref-type="bibr" rid="article-43836.r19">[19]</xref><xref ref-type="bibr" rid="article-43836.r10">[10]</xref><xref ref-type="bibr" rid="article-43836.r7">[7]</xref>&#x000a0;Rare kidney, truncal, pancreas, gastrointestinal tract, head, and neck presentations have&#x000a0;been described.<xref ref-type="bibr" rid="article-43836.r7">[7]</xref><xref ref-type="bibr" rid="article-43836.r9">[9]</xref><xref ref-type="bibr" rid="article-43836.r11">[11]</xref><xref ref-type="bibr" rid="article-43836.r13">[13]</xref><xref ref-type="bibr" rid="article-43836.r14">[14]</xref><xref ref-type="bibr" rid="article-43836.r20">[20]</xref>&#x000a0;The 5- and 10-year overall survival rates for clear cell sarcoma are&#x000a0;reported to be 47% to 67% and 25% to 51.3%, respectively, with later stages (III and IV) having worse survival rates.<xref ref-type="bibr" rid="article-43836.r9">[9]</xref><xref ref-type="bibr" rid="article-43836.r10">[10]</xref><xref ref-type="bibr" rid="article-43836.r16">[16]</xref><xref ref-type="bibr" rid="article-43836.r21">[21]</xref><xref ref-type="bibr" rid="article-43836.r10">[10]</xref></p>
      </sec>
      <sec id="article-43836.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>CCSST presents as a slowly enlarging mass adjacent to or infiltrating into tendons and aponeurosis.<xref ref-type="bibr" rid="article-43836.r15">[15]</xref><xref ref-type="bibr" rid="article-43836.r21">[21]</xref>&#x000a0;CCSST contains either&#x000a0;t(12;22)(q13;q12) or t(2;22)(q34;q12) gene translocation resulting in <italic toggle="yes">ESR1/ATF1</italic> fusion gene or <italic toggle="yes">EWSR1/CREB1</italic> fusion gene, respectively, in 70% to 90% of cases.<xref ref-type="bibr" rid="article-43836.r4">[4]</xref><xref ref-type="bibr" rid="article-43836.r5">[5]</xref><xref ref-type="bibr" rid="article-43836.r6">[6]</xref><xref ref-type="bibr" rid="article-43836.r22">[22]</xref>&#x000a0;<italic toggle="yes">EWSR1/ATF1</italic> induces expression of microphthalmia-associated transcription factor, which promotes tumor cell survival and proliferation and accounts for melanocyte differentiation in clear cell sarcoma of soft tissues.<xref ref-type="bibr" rid="article-43836.r23">[23]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-43836.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histologically, clear cell sarcoma contains nests of polygonal or spindle-shaped cells separated by sclerotic bands. The cells are characterized by pale to slightly eosinophilic cytoplasm with a single nucleus with prominent nucleoli.<xref ref-type="bibr" rid="article-43836.r11">[11]</xref><xref ref-type="bibr" rid="article-43836.r14">[14]</xref>&#x000a0;The "clear-cell" appearance represents intracellular&#x000a0;glycogen accumulation, as&#x000a0;demonstrated by the periodic acid-Schiff stain.<xref ref-type="bibr" rid="article-43836.r24">[24]</xref> Pigmented and unpigmented melanosomes, scattered multinucleated giant cells, and areas of focal necrosis are also commonly present.<xref ref-type="bibr" rid="article-43836.r15">[15]</xref><xref ref-type="bibr" rid="article-43836.r24">[24]</xref><xref ref-type="bibr" rid="article-43836.r25">[25]</xref><xref ref-type="bibr" rid="article-43836.r26">[26]</xref>&#x000a0;Mitotic figures are usually &#x0003c;10 per high power field.<xref ref-type="bibr" rid="article-43836.r12">[12]</xref>&#x000a0;Immunohistochemical staining demonstrates positivity for S-100, a marker for neural crest-derived cells, and melanocyte-specific markers HMB45 and melan-A in most clear cell sarcomas.<xref ref-type="bibr" rid="article-43836.r26">[26]</xref><xref ref-type="bibr" rid="article-43836.r18">[18]</xref><xref ref-type="bibr" rid="article-43836.r24">[24]</xref>&#x000a0;These neoplasms usually stain negative for cluster of differentiation 68, a melanoma marker, and epithelial markers smooth muscle actin, desmin, and keratin.<xref ref-type="bibr" rid="article-43836.r12">[12]</xref><xref ref-type="bibr" rid="article-43836.r18">[18]</xref><xref ref-type="bibr" rid="article-43836.r12">[12]</xref><xref ref-type="bibr" rid="article-43836.r27">[27]</xref></p>
      </sec>
      <sec id="article-43836.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The average age of patients presenting with CCSST is 34; however, case series report an age range of 2 to 90 years.<xref ref-type="bibr" rid="article-43836.r16">[16]</xref><xref ref-type="bibr" rid="article-43836.r17">[17]</xref><xref ref-type="bibr" rid="article-43836.r18">[18]</xref>&#x000a0;Patients present with slowly enlarging masses ranging from 1 to 20 cm, most commonly in the distal extremities, with or without associated pain.<xref ref-type="bibr" rid="article-43836.r7">[7]</xref><xref ref-type="bibr" rid="article-43836.r21">[21]</xref><xref ref-type="bibr" rid="article-43836.r15">[15]</xref><xref ref-type="bibr" rid="article-43836.r21">[21]</xref><xref ref-type="bibr" rid="article-43836.r15">[15]</xref>&#x000a0;Rare kidney, truncal, pancreas, gastrointestinal tract, head, and neck presentations have&#x000a0;been described.<xref ref-type="bibr" rid="article-43836.r20">[20]</xref>&#x000a0;Given its benign presentation, CCSST may be assumed to be benign at the initial presentation.</p>
      </sec>
      <sec id="article-43836.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>CCSST is usually diagnosed through physical examination, imaging studies, and histological exams. The initial evaluation should include a comprehensive history and physical examination. Patients should be asked&#x000a0;about when the mass was noticed and its growth pattern. Clinicians should also evaluate for signs and symptoms that may help in early staging. Physical examination should be focused on determining size, depth, fixation to adjacent tissues, edema, or possible neurovascular compromise. Regional lymph nodes should also be examined.</p>
        <p>Radiographs of the area of concern may reveal a soft tissue shadow consistent with a mass or, in some cases, erosive changes in the adjacent bone, especially with larger tumors in the foot and ankle.<xref ref-type="bibr" rid="article-43836.r28">[28]</xref><xref ref-type="bibr" rid="article-43836.r29">[29]</xref>&#x000a0;Magnetic resonance imaging (MRI) of CCSST reveals a mass that is often homogeneous and hypointense-to-isointense to muscle on T1-weighted images and heterogeneously high-signal on T2-weighted images.<xref ref-type="bibr" rid="article-43836.r28">[28]</xref><xref ref-type="bibr" rid="article-43836.r29">[29]</xref><xref ref-type="bibr" rid="article-43836.r28">[28]</xref><xref ref-type="bibr" rid="article-43836.r30">[30]</xref>&#x000a0;As a result, tumors with significant quantities of melanin can have higher signal intensity on T1 images and lower intensity on T2 images.<xref ref-type="bibr" rid="article-43836.r29">[29]</xref>&#x000a0;CCSST typically heterogeneously enhances with contrast.&#x000a0;MRI can also reveal areas of internal necrosis or bone invasion.&#x000a0;These imaging findings are, however, nonspecific.<xref ref-type="bibr" rid="article-43836.r28">[28]</xref></p>
        <p>Definitive diagnosis is made through tissue sampling, either by incisional biopsy, core needle biopsy, or fine needle aspiration. Histochemical analysis suggests a diagnosis of clear cell sarcoma, but cytogenetic analysis via fluorescence in situ hybridization or reverse transcription-polymerase chain reaction confirms the diagnosis with identification of either&#x000a0;t(12;22)(q13;q12) or t(2;22)(q34:q12) gene translocation.<xref ref-type="bibr" rid="article-43836.r4">[4]</xref><xref ref-type="bibr" rid="article-43836.r5">[5]</xref><xref ref-type="bibr" rid="article-43836.r31">[31]</xref><xref ref-type="bibr" rid="article-43836.r5">[5]</xref></p>
      </sec>
      <sec id="article-43836.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>For localized lesions, the treatment of choice is wide surgical resection with negative margins.<xref ref-type="bibr" rid="article-43836.r16">[16]</xref><xref ref-type="bibr" rid="article-43836.r21">[21]</xref><xref ref-type="bibr" rid="article-43836.r32">[32]</xref><xref ref-type="bibr" rid="article-43836.r16">[16]</xref><xref ref-type="bibr" rid="article-43836.r33">[33]</xref>&#x000a0;The quality of the surgical resection is an important predictor of prognosis in the setting of localized disease.<xref ref-type="bibr" rid="article-43836.r13">[13]</xref>&#x000a0;Intralesional excision has been associated with higher recurrence rates.<xref ref-type="bibr" rid="article-43836.r15">[15]</xref><xref ref-type="bibr" rid="article-43836.r34">[34]</xref>&#x000a0;Radiotherapy may improve outcomes in patients with microscopically positive margins but not in gross residual disease.<xref ref-type="bibr" rid="article-43836.r13">[13]</xref>&#x000a0;Chemotherapy is primarily employed in patients with metastatic disease. However, response rates are generally poor, with few patients having partial responses to conventional chemotherapeutic regimens such as doxorubicin-based and gemcitabine-based therapies.<xref ref-type="bibr" rid="article-43836.r13">[13]</xref><xref ref-type="bibr" rid="article-43836.r35">[35]</xref>&#x000a0;Targeted and immunotherapy are under investigation.<xref ref-type="bibr" rid="article-43836.r33">[33]</xref>&#x000a0;After surgical excision, patients should be followed closely due to the high recurrence rates and development of late metastases and local recurrence.<xref ref-type="bibr" rid="article-43836.r15">[15]</xref><xref ref-type="bibr" rid="article-43836.r16">[16]</xref><xref ref-type="bibr" rid="article-43836.r15">[15]</xref><xref ref-type="bibr" rid="article-43836.r18">[18]</xref></p>
      </sec>
      <sec id="article-43836.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of clear cell sarcoma includes tumors that stain positive for S100 and melanocyte markers, including malignant melanoma, nerve sheath tumors, and perivascular epithelioid cell tumors. Compared to melanoma, CCSST usually occurs in the younger patient population, is located in deeper tissues, is associated with aponeuroses or tendons, and commonly lacks epidermal&#x000a0;involvement.&#x000a0;<xref ref-type="bibr" rid="article-43836.r34">[34]</xref>&#x000a0;Additionally,&#x000a0;the&#x000a0;t(12;22) translocation in CCSST has not&#x000a0;been observed in malignant melanoma.<xref ref-type="bibr" rid="article-43836.r27">[27]</xref>&#x000a0;While both melanoma and CCSST stain positive for S100, HMB-45, and melan-A, melanoma is also positive for cluster of differentiation 68, while CCSST is not.<xref ref-type="bibr" rid="article-43836.r24">[24]</xref><xref ref-type="bibr" rid="article-43836.r27">[27]</xref>&#x000a0;</p>
        <p>Malignant peripheral nerve sheath tumor usually arises within large peripheral nerves and is negative for HMB-45.<xref ref-type="bibr" rid="article-43836.r36">[36]</xref>&#x000a0;Perivascular epithelioid cell family of tumors, which present commonly in the abdomen, usually in young patients' ligamentum teres of the liver.<xref ref-type="bibr" rid="article-43836.r27">[27]</xref>&#x000a0;Given the typical location of clear cell sarcoma deep in the distal extremities, the differential diagnosis includes synovial sarcoma and epithelioid sarcoma. Synovial&#x000a0;sarcoma commonly shows a&#x000a0;t(X;18)(p11.2;q11.2) translocation producing <italic toggle="yes">SYT/SSX1</italic> or <italic toggle="yes">SYT/sSSX2</italic> gene fusions, not seen in CCSST.<xref ref-type="bibr" rid="article-43836.r36">[36]</xref><xref ref-type="bibr" rid="article-43836.r34">[34]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-43836.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>Surgical resection with negative margins is recommended, especially in the setting of localized disease. When feasible, limb-sparing surgery is preferred for extremity sarcomas, but in the setting of local recurrence or larger tumors, amputation may be required.<xref ref-type="bibr" rid="article-43836.r33">[33]</xref>&#x000a0;Clear cell sarcoma tends to metastasize to regional lymph nodes, but the value of sentinel lymph node biopsy or regional lymph node dissection has no consensus.<xref ref-type="bibr" rid="article-43836.r17">[17]</xref><xref ref-type="bibr" rid="article-43836.r21">[21]</xref><xref ref-type="bibr" rid="article-43836.r37">[37]</xref></p>
      </sec>
      <sec id="article-43836.s12" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>The role of radiation in managing clear cell sarcoma of soft tissues is unclear. In general, CCSST is considered to be insensitive to radiation.<xref ref-type="bibr" rid="article-43836.r38">[38]</xref> Several case series have demonstrated no survival benefit to radiation.<xref ref-type="bibr" rid="article-43836.r16">[16]</xref><xref ref-type="bibr" rid="article-43836.r21">[21]</xref> There may, however, be a role for radiation in the case of microscopically positive margins.<xref ref-type="bibr" rid="article-43836.r13">[13]</xref><xref ref-type="bibr" rid="article-43836.r15">[15]</xref></p>
      </sec>
      <sec id="article-43836.s13" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Conventional cytotoxic chemotherapy regimens have not conferred any survival benefit in published case series.<xref ref-type="bibr" rid="article-43836.r15">[15]</xref> A minority of patients show a partial response to doxorubicin-based or gemcitabine-based regimens.<xref ref-type="bibr" rid="article-43836.r35">[35]</xref>&#x000a0;Japan Tumor registry data, including 117 patients treated from 2016 to 2017, demonstrated no difference in survival in patients treated with cytotoxic chemotherapy, immunotherapy, targeted therapy, or a combination.<xref ref-type="bibr" rid="article-43836.r39">[39]</xref>&#x000a0;Trabectin, a marine-derived alkaloid, alone or in combination with ipilimumab and nivolumab, has resulted in a partial response in some patients.<xref ref-type="bibr" rid="article-43836.r40">[40]</xref><xref ref-type="bibr" rid="article-43836.r41">[41]</xref></p>
        <p>The unique translocation and resulting gene fusion, <italic toggle="yes">EWSR1-ATF1</italic>, characteristic of CCSST, offers a target for new therapies. Studies are ongoing to investigate the effectiveness of targeted therapies, including tyrosine kinase inhibitors, mesenchymal-epithelial transition (MET) inhibitors, and immunotherapies.<xref ref-type="bibr" rid="article-43836.r33">[33]</xref>&#x000a0;Results of trials investigating crizotinib, a MET tyrosine kinase inhibitor, and tivantinib, a selective MET inhibitor, showed only partial response in less than 9% of patients.<xref ref-type="bibr" rid="article-43836.r42">[42]</xref><xref ref-type="bibr" rid="article-43836.r43">[43]</xref>&#x000a0;Another MET inhibitor, ganitumab (AMG 337), was ineffective in a trial of 8 patients with advanced or metastatic clear cell sarcoma (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT03132155">https://clinicaltrials.gov/study/NCT03132155</ext-link>). Partial responses have also been seen in patients receiving the kinase inhibitor sunitinib.<xref ref-type="bibr" rid="article-43836.r43">[43]</xref></p>
        <p>Nivolumab, a monoclonal antibody that binds PD-1, was administered to 11 patients with unresectable clear cell sarcoma in the OSCAR Trial/NCCH1510, and none of the patients had complete or partial response. A period of progression-free survival of 4.1 months was observed, though.<xref ref-type="bibr" rid="article-43836.r44">[44]</xref>&#x000a0;Administration of pembrolizumab plus radiation has been reported to result in complete response in a patient with recurrent mediastinal clear cell sarcoma.<xref ref-type="bibr" rid="article-43836.r45">[45]</xref>&#x000a0;On the other hand, the AcS&#x000e9; Pembrolizumab study included 3 patients with clear cell sarcoma, all of whom experienced disease progression.<xref ref-type="bibr" rid="article-43836.r46">[46]</xref></p>
        <p>Currently, the following trials, including patients with CCSST, are underway:</p>
        <list list-type="bullet">
          <list-item>
            <p>GFR806 CAR T&#x000a0;Cell&#x000a0;Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (NCT03618381)</p>
          </list-item>
          <list-item>
            <p>Testing Atezolizumab in People 2-17 Years Old With&#x000a0;Clear&#x000a0;Cell&#x000a0;Sarcoma&#x000a0;or Advanced Chondrosarcoma (NCT04458922)</p>
          </list-item>
          <list-item>
            <p>Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related&#x000a0;Sarcomas (NCT03600649)</p>
          </list-item>
          <list-item>
            <p>B7H3 CAR T&#x000a0;Cell&#x000a0;Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (NCT04483778)</p>
          </list-item>
          <list-item>
            <p>B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell&#x000a0;Therapy for Pediatric Patients With Solid Tumors (3CAR) (NCT04897321)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-43836.s14" sec-type="Staging">
        <title>Staging</title>
        <p>Clear cell sarcoma metastasizes most commonly to the lungs, lymph nodes, and bone. Metastatic disease has also been reported in the brain, abdominal organs, adrenal glands, skin, and heart.<xref ref-type="bibr" rid="article-43836.r8">[8]</xref><xref ref-type="bibr" rid="article-43836.r9">[9]</xref><xref ref-type="bibr" rid="article-43836.r11">[11]</xref><xref ref-type="bibr" rid="article-43836.r16">[16]</xref><xref ref-type="bibr" rid="article-43836.r11">[11]</xref><xref ref-type="bibr" rid="article-43836.r21">[21]</xref></p>
        <p>The European Society of Musculoskeletal Radiology Guidelines from 2024 recommend the following staging studies for CCSST:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chest computed tomography (CT)</p>
          </list-item>
          <list-item>
            <p>Brain MRI</p>
          </list-item>
          <list-item>
            <p>CT Abdomen and pelvis for lower extremity sarcomas to evaluate regional lymph nodes</p>
          </list-item>
          <list-item>
            <p>CT Neck for upper extremity sarcomas to evaluate regional lymph nodes</p>
          </list-item>
          <list-item>
            <p>Whole-body MRI or positron emission tomography/CT to evaluate for skeletal metastases&#x000a0;<xref ref-type="bibr" rid="article-43836.r47">[47]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-43836.s15" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Overall, the prognosis for clear cell sarcoma of soft tissues is poor, with 5-year survival rates reported as 47% to 67%.<xref ref-type="bibr" rid="article-43836.r8">[8]</xref><xref ref-type="bibr" rid="article-43836.r9">[9]</xref>&#x000a0;In the case series published, tumor size and stage consistently correlate with prognosis. At the time of diagnosis, 4% to 30% of patients already have metastatic disease.<xref ref-type="bibr" rid="article-43836.r7">[7]</xref><xref ref-type="bibr" rid="article-43836.r21">[21]</xref>&#x000a0;</p>
        <p>Data from the Japan Tumor Registry, including 117 patients, demonstrated that patients with American Joint Committee on Cancer stage I or II disease at diagnosis had a 5-year survival rate of 61%. If stage III or IV, however, the 2-year survival rate was 19%, and excision of metastatic lesions, radiation, and chemotherapy did not affect survival.<xref ref-type="bibr" rid="article-43836.r39">[39]</xref>&#x000a0;Likewise, a review from the National Cancer Database from 2004 to 2014, which included 489 patients with clear cell sarcoma, assigned a probability of survivorship at 5 years to be 75% for stage I and 15% for stage IV.<xref ref-type="bibr" rid="article-43836.r7">[7]</xref> Late development of metastatic disease, up to 20 years after diagnosis, is not uncommon.<xref ref-type="bibr" rid="article-43836.r15">[15]</xref>&#x000a0;Tumors greater than 5 cm, and in some series greater than 2 cm, were associated with a worse prognosis.<xref ref-type="bibr" rid="article-43836.r15">[15]</xref><xref ref-type="bibr" rid="article-43836.r18">[18]</xref><xref ref-type="bibr" rid="article-43836.r21">[21]</xref><xref ref-type="bibr" rid="article-43836.r18">[18]</xref><xref ref-type="bibr" rid="article-43836.r39">[39]</xref>&#x000a0;Specifically, for tumors greater than 5 cm at diagnosis, the reported incidence of metastatic disease was 79% to 100%.<xref ref-type="bibr" rid="article-43836.r9">[9]</xref><xref ref-type="bibr" rid="article-43836.r21">[21]</xref></p>
      </sec>
      <sec id="article-43836.s16" sec-type="Complications">
        <title>Complications</title>
        <p>While many patients present with indolently growing mass in the lower extremity, around 30% to 60% of patients may present pain or tenderness; a minority of patients may present with ulceration of the overlying skin.<xref ref-type="bibr" rid="article-43836.r36">[36]</xref>&#x000a0;The incidence of local recurrence for CCSST ranges from 15% to 37%.<xref ref-type="bibr" rid="article-43836.r9">[9]</xref><xref ref-type="bibr" rid="article-43836.r14">[14]</xref>&#x000a0;Untreated CCSST progresses to a widespread, deadly metastatic disease.<xref ref-type="bibr" rid="article-43836.r12">[12]</xref></p>
      </sec>
      <sec id="article-43836.s17" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be&#x000a0;educated about the overall poor prognosis of CCSST and individual risk factors for local or metastatic recurrence and be&#x000a0;provided with tumor staging&#x000a0;before and after treatment. They should also&#x000a0;be&#x000a0;encouraged to follow up closely with their clinicians, as late metastases and local recurrence are not uncommon.<xref ref-type="bibr" rid="article-43836.r21">[21]</xref></p>
      </sec>
      <sec id="article-43836.s18" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Providing patient-centered care for individuals with CCSST requires a collaborative effort among healthcare professionals, including advanced clinicians, nurses, pharmacists, and others. First and foremost, clinicians must possess the necessary clinical skills and expertise&#x000a0;when diagnosing, evaluating, and treating this condition, including proficiency in interpreting radiological findings, recognizing potential complications, and understanding the nuances of managing CCSST. Referral to a tertiary care center with experience in sarcoma treatment and management is essential. Orthopedic and surgical oncology consultations are central to treating clear cell sarcoma, especially in localized diseases.</p>
        <p>Cases of CCSST should be brought before an interprofessional tumor board. A strategic approach involving evidence-based guidelines and individualized care plans tailored to each patient's unique circumstances is vital. Ethical considerations come into play when determining treatment options and respecting patient autonomy in decision-making. Responsibilities within the interprofessional team should be clearly defined, with each member contributing their specialized knowledge and skills to optimize patient care. Effective interprofessional communication fosters a collaborative environment where information is shared, questions are encouraged, and concerns are addressed promptly.</p>
        <p>Last, care coordination is pivotal in ensuring seamless and efficient patient care. Advanced clinicians, nurses, pharmacists, and other healthcare professionals must work together to streamline the patient's journey, from diagnosis through treatment and follow-up. This coordination minimizes errors, reduces delays, and enhances patient safety, ultimately leading to improved outcomes and patient-centered care that prioritizes the well-being and satisfaction of those affected by clear cell sarcoma of soft tissues.</p>
      </sec>
      <sec id="article-43836.s19">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=43836&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=43836">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/soft-tissue-clear-cell-sarcoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=43836">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/43836/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=43836">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-43836.s20">
        <title>References</title>
        <ref id="article-43836.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Frezza</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Bonvalot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bov&#x000e9;e</surname>
                <given-names>JVMG</given-names>
              </name>
              <name>
                <surname>Callegaro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Casali</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Demetri</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Demicco</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gounder</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Gronchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Hayes-Jardon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hohenberger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kirsch</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Kleinerman</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Le Cesne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chirlaque L&#x000f3;pez</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Maestro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marcos-Gragera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martin Broto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mir</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Raut</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Razak</surname>
                <given-names>ARA</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Rutkowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sanfilippo</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Sbaraglia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Sundby Hall</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tap</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>van der Graaf</surname>
                <given-names>WTA</given-names>
              </name>
              <name>
                <surname>van Houdt</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>von Mehren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Wilky</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Won</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>CDM</given-names>
              </name>
              <name>
                <surname>Dei Tos</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Trama</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.</article-title>
            <source>Cancer</source>
            <year>2021</year>
            <month>Aug</month>
            <day>15</day>
            <volume>127</volume>
            <issue>16</issue>
            <fpage>2934</fpage>
            <page-range>2934-2942</page-range>
            <pub-id pub-id-type="pmid">33910263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mii</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyauchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hohnoki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maruyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tsutsumi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dohmae</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tamai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Konishi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamanouchi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Neural crest origin of clear cell sarcoma of tendons and aponeuroses. Ultrastructural and enzyme cytochemical study of human and nude mouse-transplanted tumours.</article-title>
            <source>Virchows Arch A Pathol Anat Histopathol</source>
            <year>1989</year>
            <volume>415</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-60</page-range>
            <pub-id pub-id-type="pmid">2499978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bridge</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sreekantaiah</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Neff</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Sandberg</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Cytogenetic findings in clear cell sarcoma of tendons and aponeuroses. Malignant melanoma of soft parts.</article-title>
            <source>Cancer Genet Cytogenet</source>
            <year>1991</year>
            <month>Mar</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-6</page-range>
            <pub-id pub-id-type="pmid">2009504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peulv&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Michot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vannier</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Tron</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hemet</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma with t(12;22) (q13-14;q12).</article-title>
            <source>Genes Chromosomes Cancer</source>
            <year>1991</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>400</fpage>
            <page-range>400-2</page-range>
            <pub-id pub-id-type="pmid">1797088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zucman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delattre</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Desmaze</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Stenman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Speleman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fletchers</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Aurias</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts.</article-title>
            <source>Nat Genet</source>
            <year>1993</year>
            <month>Aug</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>341</fpage>
            <page-range>341-5</page-range>
            <pub-id pub-id-type="pmid">8401579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reeves</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Gusterson</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Translocation t(12;22)(q13;q13) is a nonrandom rearrangement in clear cell sarcoma.</article-title>
            <source>Cancer Genet Cytogenet</source>
            <year>1992</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-3</page-range>
            <pub-id pub-id-type="pmid">1486556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzaga</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Curtin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gootee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Voth</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology and survivorship of clear cell sarcoma: a National Cancer Database (NCDB) review.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>144</volume>
            <issue>9</issue>
            <fpage>1711</fpage>
            <page-range>1711-1716</page-range>
            <pub-id pub-id-type="pmid">29961184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malchau</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hayden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hornicek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mankin</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma of soft tissues.</article-title>
            <source>J Surg Oncol</source>
            <year>2007</year>
            <month>May</month>
            <day>01</day>
            <volume>95</volume>
            <issue>6</issue>
            <fpage>519</fpage>
            <page-range>519-22</page-range>
            <pub-id pub-id-type="pmid">17192915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucas</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Nascimento</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma of soft tissues. Mayo Clinic experience with 35 cases.</article-title>
            <source>Am J Surg Pathol</source>
            <year>1992</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>1197</fpage>
            <page-range>1197-204</page-range>
            <pub-id pub-id-type="pmid">1463095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>XB</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>WB</given-names>
              </name>
            </person-group>
            <article-title>Prognostic Factors for Survival in Patients with Clear Cell Sarcoma: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database.</article-title>
            <source>Med Sci Monit</source>
            <year>2019</year>
            <month>Sep</month>
            <day>15</day>
            <volume>25</volume>
            <fpage>6950</fpage>
            <page-range>6950-6956</page-range>
            <pub-id pub-id-type="pmid">31522190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kindblom</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Lodding</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Angervall</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clear-cell sarcoma of tendons and aponeuroses. An immunohistochemical and electron microscopic analysis indicating neural crest origin.</article-title>
            <source>Virchows Arch A Pathol Anat Histopathol</source>
            <year>1983</year>
            <volume>401</volume>
            <issue>1</issue>
            <fpage>109</fpage>
            <page-range>109-28</page-range>
            <pub-id pub-id-type="pmid">6412444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hocar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Le Cesne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berissi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bonvalot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vanel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Auperin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Pechoux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bui</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Coindre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases.</article-title>
            <source>Dermatol Res Pract</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>984096</fpage>
            <pub-id pub-id-type="pmid">22693489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Casanova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bisogno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mattke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meazza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gandola</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cecchetto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Harms</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koscielniak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Treuner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma of tendons and aponeuroses in pediatric patients: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group.</article-title>
            <source>Cancer</source>
            <year>2002</year>
            <month>Jun</month>
            <day>15</day>
            <volume>94</volume>
            <issue>12</issue>
            <fpage>3269</fpage>
            <page-range>3269-76</page-range>
            <pub-id pub-id-type="pmid">12115360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eckardt</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pritchard</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Soule</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma. A clinicopathologic study of 27 cases.</article-title>
            <source>Cancer</source>
            <year>1983</year>
            <month>Oct</month>
            <day>15</day>
            <volume>52</volume>
            <issue>8</issue>
            <fpage>1482</fpage>
            <page-range>1482-8</page-range>
            <pub-id pub-id-type="pmid">6616410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deenik</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mooi</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Rutgers</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Peterse</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hart</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kroon</surname>
                <given-names>BB</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases.</article-title>
            <source>Cancer</source>
            <year>1999</year>
            <month>Sep</month>
            <day>15</day>
            <volume>86</volume>
            <issue>6</issue>
            <fpage>969</fpage>
            <page-range>969-75</page-range>
            <pub-id pub-id-type="pmid">10491522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Thway</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma (melanoma of soft parts): The Royal Marsden Hospital experience.</article-title>
            <source>Eur J Surg Oncol</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>7</issue>
            <fpage>800</fpage>
            <page-range>800-4</page-range>
            <pub-id pub-id-type="pmid">18042498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blazer</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Askew</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Feig</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Pisters</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Lev</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Cormier</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry.</article-title>
            <source>Cancer</source>
            <year>2009</year>
            <month>Jul</month>
            <day>01</day>
            <volume>115</volume>
            <issue>13</issue>
            <fpage>2971</fpage>
            <page-range>2971-9</page-range>
            <pub-id pub-id-type="pmid">19402173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bianchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Charoenlap</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cocchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Campagnoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Righi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frisoni</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Donati</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma of soft tissue: a retrospective review and analysis of 31 cases treated at Istituto Ortopedico Rizzoli.</article-title>
            <source>Eur J Surg Oncol</source>
            <year>2014</year>
            <month>May</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>505</fpage>
            <page-range>505-510</page-range>
            <pub-id pub-id-type="pmid">24560887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takemori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morizane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Satake</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Toda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Muramatsu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Higashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma in Japan: an analysis of the population-based cancer registry in Japan.</article-title>
            <source>Jpn J Clin Oncol</source>
            <year>2024</year>
            <month>Aug</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">39196756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YY</given-names>
              </name>
            </person-group>
            <article-title>Metastatic clear cell sarcoma of the pancreas: A rare case report.</article-title>
            <source>World J Clin Cases</source>
            <year>2024</year>
            <month>Mar</month>
            <day>16</day>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>1448</fpage>
            <page-range>1448-1453</page-range>
            <pub-id pub-id-type="pmid">38576799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hosono</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakayama</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Matsumine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsuchiya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Beppu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Morioka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yabe</surname>
                <given-names>H</given-names>
              </name>
              <collab>Japanese Musculoskeletal Oncology Group</collab>
            </person-group>
            <article-title>Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients.</article-title>
            <source>Cancer</source>
            <year>2007</year>
            <month>Jan</month>
            <day>01</day>
            <volume>109</volume>
            <issue>1</issue>
            <fpage>109</fpage>
            <page-range>109-16</page-range>
            <pub-id pub-id-type="pmid">17133413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Essential role of postoperative follow-up in the management of clear cell sarcoma.</article-title>
            <source>World J Clin Cases</source>
            <year>2024</year>
            <month>Aug</month>
            <day>16</day>
            <volume>12</volume>
            <issue>23</issue>
            <fpage>5299</fpage>
            <page-range>5299-5303</page-range>
            <pub-id pub-id-type="pmid">39156081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ozsolak</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Widlund</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Rozenblatt-Rosen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Granter</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Denny</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Lessnick</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Linehan</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Kung</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.</article-title>
            <source>Cancer Cell</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>473</fpage>
            <page-range>473-84</page-range>
            <pub-id pub-id-type="pmid">16766266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdouh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boujguenna</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Soleh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abkari</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rais</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Navigating diagnostic challenges-distinguishing malignant melanoma and clear cell sarcoma of soft tissues: a case report and review of the literature.</article-title>
            <source>J Med Case Rep</source>
            <year>2024</year>
            <month>May</month>
            <day>17</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>249</fpage>
            <pub-id pub-id-type="pmid">38755643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kazakos</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Galanis</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Giatromanolaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verettas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sivridis</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma of the scapula. A case report and review of the literature.</article-title>
            <source>World J Surg Oncol</source>
            <year>2006</year>
            <month>Aug</month>
            <day>07</day>
            <volume>4</volume>
            <fpage>48</fpage>
            <pub-id pub-id-type="pmid">16893467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hisaoka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Matsuyama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Imamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nishida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kuroda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Inayama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Oshiro</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakajima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ae</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>452</fpage>
            <page-range>452-60</page-range>
            <pub-id pub-id-type="pmid">18300804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodr&#x000ed;guez-Mart&#x000ed;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>S&#x000e1;ez-Rodr&#x000ed;guez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esquivel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;alez</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Cabrera</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Herrera</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma: a case mimicking primary cutaneous malignant melanoma.</article-title>
            <source>Indian J Dermatol</source>
            <year>2009</year>
            <volume>54</volume>
            <issue>2</issue>
            <fpage>168</fpage>
            <page-range>168-72</page-range>
            <pub-id pub-id-type="pmid">20101313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Valluru</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Significance of MRI in the diagnosis and differentiation of clear cell sarcoma of tendon and aponeurosis (CCSTA): A case report.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>97</volume>
            <issue>31</issue>
            <fpage>e11012</fpage>
            <pub-id pub-id-type="pmid">30075493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Beuckeleer</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>De Schepper</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vandevenne</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bloem</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Oudkerk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hauben</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Van Marck</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Somville</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vanel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Steinbach</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Guinebreti&#x000e8;re</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hogendoorn</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Mooi</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Verstraete</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zaloudek</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>MR imaging of clear cell sarcoma (malignant melanoma of the soft parts): a multicenter correlative MRI-pathology study of 21 cases and literature review.</article-title>
            <source>Skeletal Radiol</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>187</fpage>
            <page-range>187-95</page-range>
            <pub-id pub-id-type="pmid">10855466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hourani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khoury</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mourany</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shabb</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>MR appearance of clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts): radiologic-pathologic correlation.</article-title>
            <source>Skeletal Radiol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>543</fpage>
            <page-range>543-6</page-range>
            <pub-id pub-id-type="pmid">16132975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langezaal</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Graadt van Roggen</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Cleton-Jansen</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Baelde</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hogendoorn</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts).</article-title>
            <source>Br J Cancer</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>84</volume>
            <issue>4</issue>
            <fpage>535</fpage>
            <page-range>535-8</page-range>
            <pub-id pub-id-type="pmid">11207050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdollahi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khatami</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tavangar</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Clear Cell Sarcoma: A Case Report and Review of Literature.</article-title>
            <source>Int J Hematol Oncol Stem Cell Res</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-68</page-range>
            <pub-id pub-id-type="pmid">29951180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornillie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van Cann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wozniak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hompes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;ffski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Biology and management of clear cell sarcoma: state of the art and future perspectives.</article-title>
            <source>Expert Rev Anticancer Ther</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>839</fpage>
            <page-range>839-45</page-range>
            <pub-id pub-id-type="pmid">27253849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mavrogenis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stavropoulos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Papagelopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ruggieri</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathological features, diagnosis and treatment of clear cell sarcoma/melanoma of soft parts.</article-title>
            <source>Hippokratia</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>298</fpage>
            <page-range>298-302</page-range>
            <pub-id pub-id-type="pmid">25031505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smrke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frezza</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Giani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Somaiah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brahmi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Czarnecka</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rutkowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Van der Graaf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Baldi</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Duffaud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bhadri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Grimison</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mahar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network.</article-title>
            <source>ESMO Open</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>100522</fpage>
            <pub-id pub-id-type="pmid">35717681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suehara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yazawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hitachi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Terakado</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clear cell sarcoma arising from the chest wall: a case report.</article-title>
            <source>J Orthop Sci</source>
            <year>2004</year>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-4</page-range>
            <pub-id pub-id-type="pmid">15045547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>QK</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YG</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SX</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for lymph node metastasis of soft tissue sarcomas of the head, neck, and extremities, and the clinical significance of negative lymph node dissection.</article-title>
            <source>J Orthop Surg Res</source>
            <year>2022</year>
            <month>Mar</month>
            <day>18</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>167</fpage>
            <pub-id pub-id-type="pmid">35303897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ikuta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nishida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Imagama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ozaki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The current management of clear cell sarcoma.</article-title>
            <source>Jpn J Clin Oncol</source>
            <year>2023</year>
            <month>Oct</month>
            <day>04</day>
            <volume>53</volume>
            <issue>10</issue>
            <fpage>899</fpage>
            <page-range>899-904</page-range>
            <pub-id pub-id-type="pmid">37451697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujiwara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kunisada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakata</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mitsuhashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ozaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Factors associated with survival in patients with clear cell sarcoma.</article-title>
            <source>Bone Joint J</source>
            <year>2023</year>
            <month>Nov</month>
            <day>01</day>
            <volume>105-B</volume>
            <issue>11</issue>
            <fpage>1216</fpage>
            <page-range>1216-1225</page-range>
            <pub-id pub-id-type="pmid">37907082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvarez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arregui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paniagua</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvarez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez Crisostomo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>D&#x000ed;azgranados</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Calles</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agra</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A Clear Cell Sarcoma Case: A Diagnostic and Treatment Challenge, with a Promising Response to Trabectedin.</article-title>
            <source>Case Rep Oncol</source>
            <year>2023</year>
            <season>Jan-Dec</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>1542</fpage>
            <page-range>1542-1550</page-range>
            <pub-id pub-id-type="pmid">38074516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Tellez</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Younesi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chua-Alcala</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Chomoyan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Valencia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brigham</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Moradkhani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Srikureja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Federman</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma.</article-title>
            <source>Cancers (Basel)</source>
            <year>2023</year>
            <month>Jan</month>
            <day>31</day>
            <volume>15</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">36765863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wagner</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dubois</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pappo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hogg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Senzer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Waghorne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Demetri</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.</article-title>
            <source>Cancer</source>
            <year>2012</year>
            <month>Dec</month>
            <day>01</day>
            <volume>118</volume>
            <issue>23</issue>
            <fpage>5894</fpage>
            <page-range>5894-902</page-range>
            <pub-id pub-id-type="pmid">22605650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sch&#x000f6;ffski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wozniak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rutkowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lindner</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Anthoney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Duffaud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nwald</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Leahy</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Reichardt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sufliarsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van der Graaf</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Sciot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Debiec-Rychter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Cann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Marr&#x000e9;aud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raveloarivahy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Collette</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.</article-title>
            <source>Ann Oncol</source>
            <year>2017</year>
            <month>Dec</month>
            <day>01</day>
            <volume>28</volume>
            <issue>12</issue>
            <fpage>3000</fpage>
            <page-range>3000-3008</page-range>
            <pub-id pub-id-type="pmid">28950372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kakunaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ozaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawasaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tomatsuri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Okamura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kamikura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hirakawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yonemori</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510).</article-title>
            <source>Cancer</source>
            <year>2024</year>
            <month>Nov</month>
            <day>15</day>
            <volume>130</volume>
            <issue>22</issue>
            <fpage>3836</fpage>
            <page-range>3836-3844</page-range>
            <pub-id pub-id-type="pmid">39077795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marcrom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Los Santos</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Conry</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy.</article-title>
            <source>Clin Sarcoma Res</source>
            <year>2017</year>
            <volume>7</volume>
            <fpage>14</fpage>
            <pub-id pub-id-type="pmid">28725344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Chevret</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Le Cesne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brahmi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Penel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cousin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bertucci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bompas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ryckewaert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Soibinet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Boudou-Rouquette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saada Bouzid</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Soulie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Valentin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lotz</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Tosi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Neviere</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Cancel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ray-Coquard</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gambotti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Legrand</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lamrani-Ghaouti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Even</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Massard</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pembrolizumab in patients with rare and ultra-rare sarcomas (AcS&#x000e9; Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>8</issue>
            <fpage>892</fpage>
            <page-range>892-902</page-range>
            <pub-id pub-id-type="pmid">37429302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43836.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noebauer-Huhmann</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Vanhoenacker</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Vilanova</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tagliafico</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lalam</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Grieser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nikodinovska</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>de Rooy</surname>
                <given-names>JWJ</given-names>
              </name>
              <name>
                <surname>Papakonstantinou</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mccarthy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sconfienza</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Verstraete</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martel-Villagr&#x000e1;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Szomolanyi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lecouvet</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Afonso</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Albtoush</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Aringhieri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Arkun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Astr&#x000f6;m</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bazzocchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Botchu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Breitenseher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chaudhary</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dalili</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Jonge</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Mete</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Fritz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gielen</surname>
                <given-names>JLMA</given-names>
              </name>
              <name>
                <surname>Hide</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Isaac</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ivanoski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mansour</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Muntaner-Gimbernat</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Navas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O Donnell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>&#x000d6;rg&#x000fc;&#x000e7;</surname>
                <given-names>&#x0015e;</given-names>
              </name>
              <name>
                <surname>Rennie</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Resano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sanal</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Ter Horst</surname>
                <given-names>SAJ</given-names>
              </name>
              <name>
                <surname>van Langevelde</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>W&#x000f6;rtler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Koelz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Panotopoulos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Windhager</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bloem</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Soft tissue tumor imaging in adults: whole-body staging in sarcoma, non-malignant entities requiring special algorithms, pitfalls and special imaging aspects. Guidelines 2024 from the European Society of Musculoskeletal Radiology (ESSR).</article-title>
            <source>Eur Radiol</source>
            <year>2024</year>
            <month>Jul</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">39030374</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
